DCC-3116

DCC-3116 is an inhibitor of KRAS and Autophagy used in studies of MAPK / ERK Signaling and Autophagy. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and autophagic flux, lysosomal turnover, and stress adaptation in autophagy, cancer, and cell signaling models.

By inhibiting KRAS and Autophagy, DCC-3116 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and autophagic flux, lysosomal turnover, and stress adaptation. This context is compatible with phosphorylation mapping, pathway-response, and growth assays and autophagy-flux, lysosome, and cargo-clearance assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. In autophagy, cancer, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving KRAS and Autophagy
• Pathway perturbation studies connected to MAPK / ERK Signaling and Autophagy
• Concentration-response inhibition and target-dependence studies
• Phenotypic profiling in autophagy, cancer, and cell signaling models

Overall, DCC-3116 is appropriate when a defined chemical perturbant is needed to connect KRAS and Autophagy with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in autophagy, cancer, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.